These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32650667)

  • 1. Formulary restrictions may impact enrollment in pragmatic trials and limit generalizability of findings to vulnerable populations.
    Segal JB;
    Clin Trials; 2020 Dec; 17(6):729-731. PubMed ID: 32650667
    [No Abstract]   [Full Text] [Related]  

  • 2. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences.
    Oude Rengerink K; Kalkman S; Collier S; Ciaglia A; Worsley SD; Lightbourne A; Eckert L; Groenwold RHH; Grobbee DE; Irving EA;
    J Clin Epidemiol; 2017 Sep; 89():173-180. PubMed ID: 28502808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Per-Protocol Analyses of Pragmatic Trials.
    Hernán MA; Robins JM
    N Engl J Med; 2017 Oct; 377(14):1391-1398. PubMed ID: 28976864
    [No Abstract]   [Full Text] [Related]  

  • 4. Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity.
    Koehler M; Donnelly ET; Kalanovic D; Dagher R; Rothenberg ML
    Ann Oncol; 2016 Jul; 27(7):1342-8. PubMed ID: 27029709
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations.
    Verma D; Ashkar C; Saab S
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):9-12. PubMed ID: 33073620
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis C: who should be treated?
    Campbell MS
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):77-9. PubMed ID: 16447299
    [No Abstract]   [Full Text] [Related]  

  • 7. Leveraging electronic health record data for pragmatic randomized trials.
    Roe MT
    Clin Trials; 2020 Aug; 17(4):368-369. PubMed ID: 32668979
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of health plan administrative claims data in participant recruitment for pragmatic clinical trials: An Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) example.
    Shi Q; Shambhu S; Marshall A; Rose-Kennedy E; Robertson H; Paullin M; Jones WS; Cziraky M; Haynes K
    Clin Trials; 2020 Apr; 17(2):212-222. PubMed ID: 32009464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pragmatic study designs for older adults with cancer: Report from the U13 conference.
    Nipp RD; Yao NA; Lowenstein LM; Buckner JC; Parker IR; Gajra A; Morrison VA; Dale W; Ballman KV
    J Geriatr Oncol; 2016 Jul; 7(4):234-41. PubMed ID: 27197914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pragmatic trials revisited: applicability is about individualization.
    Sacristán JA; Dilla T
    J Clin Epidemiol; 2018 Jul; 99():164-166. PubMed ID: 29432859
    [No Abstract]   [Full Text] [Related]  

  • 11. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
    Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
    Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
    Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
    Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The shrinking scope of pragmatic trials: a methodological reflection on their domain of applicability.
    Pawson R
    J Clin Epidemiol; 2019 Mar; 107():71-76. PubMed ID: 30500404
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial.
    Cocoros NM; Pokorney SD; Haynes K; Garcia C; Al-Khalidi HR; Al-Khatib SM; Archdeacon P; Goldsack JC; Harkins T; Lin ND; Martin D; McCall D; Nair V; Parlett L; Temple R; McMahill-Walraven C; Granger CB; Platt R
    Clin Trials; 2019 Feb; 16(1):90-97. PubMed ID: 30445835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
    Nguyen OK; Dore GJ; Kaldor JM; Hellard ME;
    Int J Drug Policy; 2007 Oct; 18(5):447-51. PubMed ID: 17854736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pragmatic Trials.
    Ford I; Norrie J
    N Engl J Med; 2016 Aug; 375(5):454-63. PubMed ID: 27518663
    [No Abstract]   [Full Text] [Related]  

  • 17. A guide to research partnerships for pragmatic clinical trials.
    Johnson KE; Tachibana C; Coronado GD; Dember LM; Glasgow RE; Huang SS; Martin PJ; Richards J; Rosenthal G; Septimus E; Simon GE; Solberg L; Suls J; Thompson E; Larson EB
    BMJ; 2014 Dec; 349():g6826. PubMed ID: 25446054
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing the design of pragmatic trials: key issues remain.
    Caro JJ; Ishak KJ
    J Comp Eff Res; 2012 Jul; 1(4):319-27. PubMed ID: 24237466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned in methods and analyses for pragmatic studies.
    Eckardt P; Erlanger AE
    Nurs Outlook; 2018 Sep; 66(5):446-454. PubMed ID: 30131168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understudied populations with hepatitis C.
    Strader DB
    Hepatology; 2002 Nov; 36(5 Suppl 1):S226-36. PubMed ID: 12407598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.